All In Biotech

Drug Trial Radar · NCT05254327

Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

A Randomized Phase 2 Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With and Without BMX-001 as Part of Total Neoadjuvant Therapy in Patients With Newly Diagnosed Locally Advanced Rectal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

118

Planned (sponsor's estimate)

Start

Aug 15, 2022

Primary completion

May 2030

Study completion Jun 2034

Sponsor

Lead sponsor
University of NebraskaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BioMimetix JV, LLC
First posted
Feb 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients.

Conditions

  • Rectal Cancer

Interventions

  • BMX-001Drug

    Loading dose of 28 mg per subject, followed by maintenance doses of 14 mg per subject twice per week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of BMX-001 as measured by Grade 3 and above associated with gastrointestinal ToxicitiesTime frame: Three weeks (During and 2 weeks after RT)
  2. Efficacy of BMX-001 as measured by Grade 3 and above associated with genitourinary ToxicitiesTime frame: Three weeks (During and 2 weeks after RT)
  3. Efficacy of BMX-001 as measured by Grade 3 and above associated with skin ToxicitiesTime frame: Three weeks (During and 2 weeks after RT)
  4. Efficacy of BMX-001 as measured by Grade 3 and above associated with hematologic ToxicitiesTime frame: Three weeks (During and 2 weeks after RT)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • UT Health San Antonio MD Anderson Cancer Center

    San Antonio, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.